TokenPost topic
1 TokenPost story is tagged Aktis Oncology. The newest appear first.
Research and development expenses rose to $32.1 million as the company began a third Phase 1b trial and expects its cash to fund operations into 2029.
Nov 12, 2026, 12:55 PM EST · Business
